XML 169 R112.htm IDEA: XBRL DOCUMENT v3.25.0.1
Goodwill and other intangible assets - Detailed Information for Principal Marketed Products (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 22,629 € 24,319 € 21,640
Marketed products      
Disclosure of detailed information about intangible assets [line items]      
Concentration risk percentage 95.00%    
Other intangible assets € 12,700 € 16,600 12,700
Useful life, intangible assets other than goodwill (in years)   10 years  
Total: principal marketed products incl. Opella products presented in "Assets held for sale"      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 14,795 € 15,927 11,863
Intangible Assets Other Than Goodwill, Discontinued Operations 12,002 13,055 9,429
Genzyme      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] € 59 208 621
Useful life, intangible assets other than goodwill (in years) [1],[2] 10 years    
Remaining amortisation period of intangible assets material to entity [1],[3] 2 years    
Boehringer Ingelheim Consumer Healthcare      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] € 1,764 1,806 2,037
Useful life, intangible assets other than goodwill (in years) [1],[2] 17 years    
Remaining amortisation period of intangible assets material to entity [1],[3] 10 years    
Aventis      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] € 39 43 58
Useful life, intangible assets other than goodwill (in years) [1],[2] 9 years    
Remaining amortisation period of intangible assets material to entity [1],[3] 10 years    
Chattem      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] € 482 501 574
Useful life, intangible assets other than goodwill (in years) [1],[2] 23 years    
Remaining amortisation period of intangible assets material to entity [1],[3] 10 years    
Protein Sciences      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] € 381 420 498
Useful life, intangible assets other than goodwill (in years) [1],[2] 13 years    
Remaining amortisation period of intangible assets material to entity [1],[3] 6 years    
Ablynx      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] € 1,083 1,220 1,357
Useful life, intangible assets other than goodwill (in years) [1],[2] 14 years    
Remaining amortisation period of intangible assets material to entity [1],[3] 8 years    
Bioverativ      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] € 4,349 5,152 4,836
Useful life, intangible assets other than goodwill (in years) [1],[2] 13 years    
Remaining amortisation period of intangible assets material to entity [1],[3] 8 years    
Rezurock      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 1,513 1,580 1,702
Useful life, intangible assets other than goodwill (in years) [2] 12 years    
Remaining amortisation period of intangible assets material to entity [3] 9 years    
Tzield      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 2,339 2,405 0
Useful life, intangible assets other than goodwill (in years) [2] 12 years    
Remaining amortisation period of intangible assets material to entity [3] 11 years    
Beyfortus      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 2,087 1,870 180
Useful life, intangible assets other than goodwill (in years) [2] 17 years    
Remaining amortisation period of intangible assets material to entity [3] 16 years    
Qunol      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 699 € 722 € 0
Useful life, intangible assets other than goodwill (in years) [2] 10 years    
Remaining amortisation period of intangible assets material to entity [3] 8 years    
Gross value | Total: principal marketed products incl. Opella products presented in "Assets held for sale"      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 68,753    
Intangible Assets Other Than Goodwill, Discontinued Operations 60,214    
Gross value | Genzyme      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] 10,600    
Gross value | Boehringer Ingelheim Consumer Healthcare      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] 3,520    
Gross value | Aventis      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] 34,175    
Gross value | Chattem      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] 1,406    
Gross value | Protein Sciences      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] 886    
Gross value | Ablynx      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] 1,966    
Gross value | Bioverativ      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] 8,375    
Gross value | Rezurock      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 2,033    
Gross value | Tzield      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 2,714    
Gross value | Beyfortus      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 2,288    
Gross value | Qunol      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 790    
Accumulated amortization & impairment | Total: principal marketed products incl. Opella products presented in "Assets held for sale"      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (53,958)    
Intangible Assets Other Than Goodwill, Discontinued Operations (48,212)    
Accumulated amortization & impairment | Genzyme      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] (10,541)    
Accumulated amortization & impairment | Boehringer Ingelheim Consumer Healthcare      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] (1,756)    
Accumulated amortization & impairment | Aventis      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] (34,136)    
Accumulated amortization & impairment | Chattem      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] (924)    
Accumulated amortization & impairment | Protein Sciences      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] (505)    
Accumulated amortization & impairment | Ablynx      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] (883)    
Accumulated amortization & impairment | Bioverativ      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets [1] (4,026)    
Accumulated amortization & impairment | Rezurock      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (520)    
Accumulated amortization & impairment | Tzield      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (375)    
Accumulated amortization & impairment | Beyfortus      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (201)    
Accumulated amortization & impairment | Qunol      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € (91)    
Bottom of range      
Disclosure of detailed information about intangible assets [line items]      
Useful life, intangible assets other than goodwill (in years) 1 year    
Top of range      
Disclosure of detailed information about intangible assets [line items]      
Useful life, intangible assets other than goodwill (in years) 25 years    
[1] (c)Commercialized products derived from the acquisition of these companies. In the case of Bioverativ, the product Enjaymo was sold to Recordati in 2024
(see Note D.1.).
[2] (a)Weighted averages. The amortization periods for these products vary between 1 and 25 years.
[3] (b)Weighted averages.